By Samuel Howard ( January 21, 2010, 7:04 PM EST) -- With a trial in the multidistrict litigation over Pfizer Inc.'s alleged off-label marketing of Neurontin just a month away, Kaiser Foundation Health Plan Inc. is attacking the credibility of Pfizer's expert testimony, contending the doctors embraced sham clinical results when vouching for the drug's effectiveness as a treatment for bipolar disorder and migraines....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.